Moderna, Inc.
(NASDAQ : MRNA)

( )
MRNA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 16.35%127.030.0%$2227.08m
BIIBBiogen, Inc. 0.84%243.781.7%$657.15m
AMGNAmgen, Inc. 2.04%224.811.3%$567.96m
GILDGilead Sciences, Inc. 0.89%60.031.0%$514.37m
NVAXNovavax, Inc. 22.51%125.6992.9%$508.55m
BNTXBioNTech SE 4.79%109.990.0%$483.37m
VRTXVertex Pharmaceuticals, Inc. 3.95%226.711.9%$475.11m
REGNRegeneron Pharmaceuticals, Inc. 1.13%514.052.7%$473.60m
ILMNIllumina, Inc. 4.29%317.033.5%$393.59m
APVOAptevo Therapeutics, Inc. 1.32%44.3918.3%$233.60m
SGENSeagen Inc. 2.22%169.125.8%$182.62m
EXASEXACT Sciences Corp. 2.00%118.1919.6%$179.47m
ALXNAlexion Pharmaceuticals, Inc. 0.73%123.832.0%$157.60m
HALOHalozyme Therapeutics, Inc. -2.21%40.2318.4%$131.67m
SRNESorrento Therapeutics, Inc. 18.12%8.151.4%$127.58m

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.